A First-in-man Phase I/II Study of Oral ONC201 in Patients With Advanced Cancer
Status:
Withdrawn
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
ONC201 is a new potential drug that kills cancer cells but not normal cells in laboratory
studies. This clinical trial will be the first evaluation of ONC201 in humans and will enroll
patients with advanced cancer. This trial includes a phase I portion that will evaluate the
safety of ONC201 and the recommended dose for the phase II portion. The phase II portion will
evaluate the initial efficacy profile of ONC201 in select types of cancer.